ArticleThe journal of headache and pain2023

Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 months.

Emma Troy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.